止哮汤联合舒利迭治疗支气管哮喘的临床效果(1)
[摘要] 目的 验证治疗支气管哮喘采取止哮汤联合舒利迭的临床治疗成效。方法 该次的68例研究对象均方便选自该院2016年1月—2017年5月期间接收的支气管哮喘患者,将其按照随机、平均方式分为观察组(n=34)和对照组(n=34)。对照组采取甲泼尼龙治疗方式,而观察组采取止哮汤联合舒利迭治疗方式,观察两组患者的治疗成效。 结果 观察组的治疗总成效为94.12%,明显高于对照组的67.65%,差异有统计学意义(χ2=4.621,P<0.05);另外,治疗后观察组患者的FVC(80.39±14.32)L、FEVI(79.21±14.02)L、PEFR(4.69±1.08)L等指标均明显优于对照组的FVC(77.21±13.25)L、FEVI(76.25±13.20)L、PEFR(4.06±1.03)L,差异统计学有意义(t=6.351、4.554、4.001,P=0.000、0.000、0.015)。结论 对支气管哮喘患者实施止哮汤联合舒利迭治疗方式,可有效缓解患者病情,临床疗效明显,值得进一步推广。
[关键词] 支气管哮喘;止哮汤;舒利迭;甲泼尼龙
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0175-03
[Abstract] Objective This paper tries to verify the clinical efficacy of treatment of bronchial asthma by taking Zhixiao decoction combined with Seretide. Methods 68 subjects in this study were convenient selected from patients with bronchial asthma received from January 2016 to May 2017 in this hospital. They were randomly divided into observation group (n=34) and control group (n= 34). The control group was treated with methylprednisolone, and the observation group was treated with Zhixiao Decoction combined with Seretide, and the treatment effect of the two groups of patients was observed. Results The total therapeutic effect of the observation group was 94.12%, significantly higher than 67.65% in the control group, and the difference was statistically significant (χ2=4.621, P<0.05). In addition, the observation group of patients after treatment of FVC (80.39±14.32)L, FEVI (79.21±14.02)L, PEFR (4.69±1.08)L and other indicators were significantly better than that of control group FVC (77.21±13.25 )L, FEVI (76.25±13.20)L, PEFR (4.06±1.03)L, statistically significant differences (t=6.351, 4.554, 4.001, (P=0.000, 0.000, 0.015). Conclusion The implementation of Zhixiao decoction combined with Seretide in the treatment of patients with bronchial asthma can effectively alleviate the patient's condition, and the clinical curative effect is obvious, it is worthy of further promotion.
[Key words] Bronchial Asthma; Zhixiao decoction; Seridite; Methylprednisolone
目前,臨床上出现支气管哮喘疾病的现象不断增多,且逐年呈上升趋势,一旦出现此病症,患者就会出现胸闷、咳嗽、呼吸困难、胸痛等症状,如果病情十分严重,将会出现呼吸衰竭、心脏病等现象,严重危及患者的生命[1-2]。所以对其进行有效治疗至关重要。该文研究方便选取了该院2016年1月—2017年5月期间接收的68例支气管哮喘患者进行了有关研究和探讨,报道如下。
1 资料与方法
1.1 一般资料
该次的68例研究对象均方便选自该院接收的支气管哮喘患者,平均分为观察组和对照组,各34例。对照组有男患17例,女患17例;年龄最小为20岁,最大为45岁,平均年龄为(31.35±2.33)岁;观察组有女患15例,男患19例;最小年龄为21岁,最大年龄为46岁,平均年龄为(30.54±2.13)岁。两组患者在基本资料方面差异无统计学意义(P>0.05)。
1.1.1 入组标准 此次研究已得到该院伦理委员会批准[3];符合支气管哮喘诊断标准;且患者自愿参与,并签署知情研究协议书。, 百拇医药(熊智)
[关键词] 支气管哮喘;止哮汤;舒利迭;甲泼尼龙
[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742(2018)05(b)-0175-03
[Abstract] Objective This paper tries to verify the clinical efficacy of treatment of bronchial asthma by taking Zhixiao decoction combined with Seretide. Methods 68 subjects in this study were convenient selected from patients with bronchial asthma received from January 2016 to May 2017 in this hospital. They were randomly divided into observation group (n=34) and control group (n= 34). The control group was treated with methylprednisolone, and the observation group was treated with Zhixiao Decoction combined with Seretide, and the treatment effect of the two groups of patients was observed. Results The total therapeutic effect of the observation group was 94.12%, significantly higher than 67.65% in the control group, and the difference was statistically significant (χ2=4.621, P<0.05). In addition, the observation group of patients after treatment of FVC (80.39±14.32)L, FEVI (79.21±14.02)L, PEFR (4.69±1.08)L and other indicators were significantly better than that of control group FVC (77.21±13.25 )L, FEVI (76.25±13.20)L, PEFR (4.06±1.03)L, statistically significant differences (t=6.351, 4.554, 4.001, (P=0.000, 0.000, 0.015). Conclusion The implementation of Zhixiao decoction combined with Seretide in the treatment of patients with bronchial asthma can effectively alleviate the patient's condition, and the clinical curative effect is obvious, it is worthy of further promotion.
[Key words] Bronchial Asthma; Zhixiao decoction; Seridite; Methylprednisolone
目前,臨床上出现支气管哮喘疾病的现象不断增多,且逐年呈上升趋势,一旦出现此病症,患者就会出现胸闷、咳嗽、呼吸困难、胸痛等症状,如果病情十分严重,将会出现呼吸衰竭、心脏病等现象,严重危及患者的生命[1-2]。所以对其进行有效治疗至关重要。该文研究方便选取了该院2016年1月—2017年5月期间接收的68例支气管哮喘患者进行了有关研究和探讨,报道如下。
1 资料与方法
1.1 一般资料
该次的68例研究对象均方便选自该院接收的支气管哮喘患者,平均分为观察组和对照组,各34例。对照组有男患17例,女患17例;年龄最小为20岁,最大为45岁,平均年龄为(31.35±2.33)岁;观察组有女患15例,男患19例;最小年龄为21岁,最大年龄为46岁,平均年龄为(30.54±2.13)岁。两组患者在基本资料方面差异无统计学意义(P>0.05)。
1.1.1 入组标准 此次研究已得到该院伦理委员会批准[3];符合支气管哮喘诊断标准;且患者自愿参与,并签署知情研究协议书。, 百拇医药(熊智)
参见:首页 > 医疗版 > 疾病专题 > 呼吸内科 > 气管、支气管疾病 > 支气管哮喘